Keith Moore, DO
Gastroenterology · Orlando, FLNPI 1760471304
Payments from drug & device makers
Across 639 payments — averaging $272.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$140K
- Bristol Myers Squibb$25K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$918
- Johnson & Johnson$703
- plus $3K from 27 others
Across 1 payment — averaging $12,840 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$13K
What the payments were for
- Food & beverage$8,66198%
- Education$2182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 8 | $139,931 |
| Bristol Myers Squibb | 37 | $25,425 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 208 | $2,217 |
| AbbVie(2 entities) | 115 | $1,944 |
| Takeda Pharmaceuticals U.S.A., Inc. | 72 | $918 |
| Johnson & Johnson(3 entities) | 35 | $703 |
| Intercept Pharmaceuticals, Inc. | 16 | $313 |
| Nestle Healthcare Nutrition Inc. | 20 | $306 |
| Merck | 13 | $251 |
| Ironwood Pharmaceuticals, Inc | 24 | $227 |
| Pfizer | 13 | $212 |
| Redhill Biopharma Inc. | 9 | $200 |
| Madrigal Pharmaceuticals | 10 | $184 |
| Gilead | 9 | $138 |
| UCB, Inc. | 10 | $134 |
| Ardelyx, Inc. | 5 | $118 |
| Braintree Laboratories, Inc. | 6 | $103 |
| Phathom Pharmaceuticals, Inc. | 4 | $93 |
| Sanofi | 4 | $81 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Romark Laboratories, LC | 2 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $47 |
| Vivus LLC | 2 | $44 |
| Lucid Diagnostics Inc. | 2 | $41 |
| Celltrion USA Inc. | 2 | $37 |
| Medtronic | 2 | $31 |
| Axonics, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $20 |
| Covidien LP | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Capsovision, Inc. | 1 | $17 |
| QOL Medical, LLC | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
How this compares
$173,925 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 12 | $81,348 |
| LinzessLinaclotide | 37 | $36,455 |
| XifaxanRifaximin | 12 | $36,392 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 66 | $10,775 |
| Famotidine | 292 | $7,062 |
| Lubiprostone | 41 | $6,461 |
| Esomeprazole Magnesium | 90 | $5,890 |
| Pantoprazole Sodium | 490 | $5,752 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 25 | $4,221 |
| Ursodiol | 21 | $3,895 |
| Mesalamine | 17 | $3,325 |
| Dicyclomine Hcl | 59 | $2,849 |
| Colestipol Hcl | 37 | $2,715 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 42 | $2,637 |
| Omeprazole | 184 | $2,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,944 | $117,80349 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $2,217 | $36,39212 claims |
| Braintree Laboratories, Inc.Sutab | $103 | $10,77566 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Orlando
- Henry LevineOrlando$3.4M
- Samuel GidayOrlando$2.1M
- Jennifer Seminerio-DiehlOrlando$1.7M
- Huy TranOrlando$1.2M
- Jason KorenblitOrlando$666K
- Saurabh AgrawalOrlando$584K
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.